Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.